Please wait a minute...
Reviews in Cardiovascular Medicine  2021, Vol. 22 Issue (3): 677-690     DOI: 10.31083/j.rcm2203077
Review Previous articles | Next articles
The relevance of specific heart failure outpatient programs in the COVID era: an appropriate model for every disease
Matteo Beltrami1, *(), Simone Bartolini1, Massimo Milli1, Alberto Palazzuoli2
1Cardiology Unit, San Giovanni di Dio Hospital, 50142 Florence, Italy
2Cardiovascular Diseases Unit, Department of Internal Medicine, Le Scotte Hospital, University of Siena, 53100 Siena, Italy
Download:  PDF(2643KB)  ( 540 ) Full text   ( 17 )
Export:  BibTeX | EndNote (RIS)      
Abstract:
Heart Failure (HF) is characterized by an elevated readmission rate, with almost 50% of events occurring after the first episode over the first 6 months of the post-discharge period. In this context, the vulnerable phase represents the period when patients elapse from a sub-acute to a more stabilized chronic phase. The lack of an accurate approach for each HF subtype is probably the main cause of the inconclusive data in reducing the trend of recurrent hospitalizations. Most care programs are based on the main diagnosis and the HF stages, but a model focused on the specific HF etiology is lacking. The HF clinic route based on the HF etiology and the underlying diseases responsible for HF could become an interesting approach, compared with the traditional programs, mainly based on non-specific HF subtypes and New York Heart Association class, rather than on detailed etiologic and epidemiological data. This type of care may reduce the 30-day readmission rates for HF, increase the use of evidence-based therapies, prevent the exacerbation of each comorbidity, improve patient compliance, and decrease the use of resources. For all these reasons, we propose a dedicated outpatient HF program with a daily practice scenario that could improve the early identification of symptom progression and the quality-of-life evaluation, facilitate the access to diagnostic and laboratory tools and improve the utilization of financial resources, together with optimal medical titration and management.
Key words:  Heart failure      Hypertrophic cardiomyopathy      Dilated cardiomyopathy      Ischemic cardiomyopathy      Valvular heart disease      COVID-19      Telemedicine      Heart failure outpatient programs     
Submitted:  31 May 2021      Revised:  19 July 2021      Accepted:  28 July 2021      Published:  24 September 2021     
*Corresponding Author(s):  Matteo Beltrami     E-mail:  beltrami.matteo1@gmail.com

Cite this article: 

Matteo Beltrami, Simone Bartolini, Massimo Milli, Alberto Palazzuoli. The relevance of specific heart failure outpatient programs in the COVID era: an appropriate model for every disease. Reviews in Cardiovascular Medicine, 2021, 22(3): 677-690.

URL: 

https://rcm.imrpress.com/EN/10.31083/j.rcm2203077     OR     https://rcm.imrpress.com/EN/Y2021/V22/I3/677

[1] Peter A. McCullough, Raphael B. Stricker, Harvey A. Risch. Role of hydroxychloroquine in multidrug treatment of COVID-19[J]. Reviews in Cardiovascular Medicine, 2021, 22(3): 545-546.
[2] Luca Di Lullo, Antonio Bellasi, Vincenzo Barbera, Claudio Ronco. Cardionephrology and cardiorenal disease in Italy: state of the art[J]. Reviews in Cardiovascular Medicine, 2021, 22(3): 563-572.
[3] Hongbo Gan, Heng Tang, Yujie Huang, Dan Wang, Peng Pu, Zhong Zuo. The 'diamond' approach to personalized drug treatment of heart failure with reduced ejection fraction[J]. Reviews in Cardiovascular Medicine, 2021, 22(3): 573-584.
[4] Ronald O. Morales, Francesc Barbosa, Nuria Farre. Peritoneal dialysis in heart failure: focus on kidney and ventricular dysfunction[J]. Reviews in Cardiovascular Medicine, 2021, 22(3): 649-657.
[5] Sarah Fitzsimons, Robert N Doughty. Role of transthoracic echocardiogram in acute heart failure[J]. Reviews in Cardiovascular Medicine, 2021, 22(3): 741-754.
[6] Martha Kyriakou, Anastasia Samara, Katerina Philippou, Ioanna Lakatamitou, Ekaterini Lambrinou. A qualitative meta-synthesis of patients with heart failure perceived needs[J]. Reviews in Cardiovascular Medicine, 2021, 22(3): 853-864.
[7] Yaowang Lin, Yang Chen, Jie Yuan, Xinli Pang, Huadong Liu, Shaohong Dong, Qiuling Chen. Intravenous morphine use in acute heart failure increases adverse outcomes: a meta-analysis[J]. Reviews in Cardiovascular Medicine, 2021, 22(3): 865-872.
[8] Ali Yazdanyar, Muhammad Haisum Maqsood, Jerald Pelayo, Julien Sanon, Eduardo Quintero, Kevin Bryan Lo, Roy O. Mathew, Janani Rangaswami. Clinical outcomes in patients with heart failure with and without cirrhosis: an analysis from the national inpatient sample[J]. Reviews in Cardiovascular Medicine, 2021, 22(3): 925-929.
[9] Rafle Fernandez, Francesco Nappi, Sofia A. Horvath, Sarah A. Guigui, Christos G. Mihos. Echocardiographic and clinical outcomes of patients undergoing septal myectomy plus anterior mitral leaflet extension for hypertrophic cardiomyopathy[J]. Reviews in Cardiovascular Medicine, 2021, 22(3): 983-990.
[10] Matthieu MILLION, Jean-Christophe LAGIER, Hervé TISSOT-DUPONT, Isabelle RAVAUX, Catherine DHIVER, Christelle TOMEI, Nadim CASSIR, Léa DELORME, Sébastien CORTAREDONA, Sophie AMRANE, Camille AUBRY, Karim BENDAMARDJI, Cyril BERENGER, Barbara DOUDIER, Sophie EDOUARD, Marie HOCQUART, Morgane MAILHE, Coralie PORCHETO, Piseth SENG, Catherine TRIQUET, Stéphanie GENTILE, Elisabeth JOUVE, Audrey GIRAUD-GATINEAU, Herve CHAUDET, Laurence CAMOIN-JAU, Philippe COLSON, Philippe GAUTRET, Pierre-Edouard FOURNIER, Baptiste MAILLE, Jean-Claude DEHARO, Paul HABERT, Jean-Yves GAUBERT, Alexis JACQUIER, Stéphane HONORE, Katell GUILLON-LORVELLEC, Yolande OBADIA, Philippe PAROLA, Philippe BROUQUI, Didier RAOULT. Early combination therapy with hydroxychloroquine and azithromycin reduces mortality in 10,429 COVID-19 outpatients[J]. Reviews in Cardiovascular Medicine, 2021, 22(3): 1063-1072.
[11] Janani Rangaswami. Closing gaps in the care of patients with heart-kidney disease: the time is now[J]. Reviews in Cardiovascular Medicine, 2021, 22(2): 257-258.
[12] Lee Stoner, Mark Faghy, Ryan Conners. COVID-19 infection and cardiometabolic complications: short- and long-term treatment and management considerations[J]. Reviews in Cardiovascular Medicine, 2021, 22(2): 263-265.
[13] Melanie McGinlay, Sam Straw, Jacob Jagger, Bako Nouri, John Gierula, Klaus K Witte. Impact of the COVID-19 pandemic on the management of chronic heart failure[J]. Reviews in Cardiovascular Medicine, 2021, 22(2): 271-276.
[14] Edoardo Pancaldi, Greta Pascariello, Giuliana Cimino, Angelica Cersosimo, Ludovica Amore, Fabio Alghisi, Nicola Bernardi, Emiliano Calvi, Carlo Mario Lombardi, Enrico Vizzardi, Marco Metra. Thrombotic risk in patients with COVID-19[J]. Reviews in Cardiovascular Medicine, 2021, 22(2): 277-286.
[15] Ibrahim AlShahrani, Jagadish Hosmani, Vidya Gurram Shankar, Abdulaziz AlShahrani, Rafi Ahmad Togoo, Syed M Yassin, Shahrukh Khan, Shankargouda Patil. COVID-19 and cardiovascular system—a comprehensive review[J]. Reviews in Cardiovascular Medicine, 2021, 22(2): 343-351.
No Suggested Reading articles found!